Skip to main content

Table 1 Distribution of SCUBE3 expression with clinicopathologic characteristics of breast cancer (N = 137)

From: SCUBE3 serves as an independent poor prognostic factor in breast cancer

Variable

 

SCUBE3 expression

p-value

Total

Low

High

 

Number

137

106 (77.4%)

31 (22.6%)

 

Age, years

55.9 ± 11.7

55.9 ± 11.8

55.7 ± 11.7

0.952

Histologic grade

   

0.514

 2

95 (69.3%)

81 (85.3%)

14 (14.7%)

 

 3

42 (30.7%)

25 (59.5%)

17 (40.5%)

 

Histologic type

   

0.399

 Invasive ductal

114 (83.2%)

86 (75.4%)

28 (24.6%)

 

 Other

23 (16.8%)

20 (87.0%)

3 (13.0%)

 

Tumor size, cm

   

0.0798

  ≤ 2

55 (40.1%)

42 (76.4%)

13 (23.6%)

 

  > 2

82 (59.9%)

64 (78.0%)

18 (22.0%)

 

Lymph node metastasis

   

0.907

 Negative

72 (52.6%)

55 (76.4%)

17 (23.6%)

 

 Positive

65 (47.4%)

51 (78.5%)

14 (21.5%)

 

TMN stage

   

0.0725

 I

39 (28.5%)

30 (76.9%)

9 (23.1%)

 

 II

52 (38.0%)

41 (78.8%)

11 (21.2%)

 

 III

46 (33.6%)

35 (76.1%)

11 (23.9%)

 

ER

   

0.018

 Negative

31 (23.1%)

19 (61.3%)

12 (38.7%)

 

 Positive

103 (76.9%)

55 (53.4%)

48 (46.6%)

 

 Missing

3

2

1

 

PR

   

0.015

 Negative

24 (17.8%)

15 (62.5%)

9 (37.5%)

 

 Positive

111 (82.2%)

60 (54.1%)

51 (45.9%)

 

 Missing

2

1

1

 

HER2

   

0.039

 Negative

109 (87.9%)

64 (58.7%)

45 (41.3%)

 

 Positive

15 (12.1%)

9 (60.0%)

6 (40.0%)

 

 Missing

13

11

2

 

E-cadherin

   

0.020

 Negative

45 (38.1%)

30 (66.7%)

15 (33.3%)

 

 Positive

73 (61.9%)

62 (84.9%)

11 (15.1%)

 

 Missing

Subtypes

19

14

5

0.706

Luminal A

79 (62.2%)

35 (44.3%)

44 (55.7%)

 

Luminal B

17 (13.4%)

9 (53.0%)

8 (47.1%)

 

HER2

16 (12.6%)

6 (37.5%)

10 (62.5%)

 

TNBC

25 (19.7%)

10 (40%)

15 (60.0%)

 

Missing

10

3

7

 

Recurrence

   

0.855

 Yes

38 (27.7%)

29 (76.3%)

9 (23.7%)

 

 No

99 (72.3%)

77 (77.8%)

22 (22.2%)

 

Survival state

   

0.032

 Survival

108 (78.8%)

89 (82.4%)

19 (17.6%)

 

 Death

29 (21.2%)

12 (41.4%)

17 (58.6%)

 
  1. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor; TMN stage was according to the seventh edition of the Guidelines for the American Journal of Critical Care. Variables are expressed as n (%) or the mean ± SD